natgillin/translations-raw huggingface dataset:
Treatment with insulin can cause hypoglycaemia, for clinical signs and appropriate treatment, see section 4.10.
Zdravljenje z insulinom lahko povzroči hipoglikemijo; glejte poglavje 4.10 za klinične znake in ustrezno zdravljenje.
Treatment with Intelence should be started by a doctor who has experience in the treatment of HIV infection.
Zdravljenje z zdravilom Intelence lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Treatment with Invirase should be started by a doctor who has experience in the treatment of HIV infection.
Zdravljenje z zdravilom Invirase lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužb z virusom HIV.
Treatment with IRESSA should be initiated and supervised by a physician experienced in the use of anticancer therapies.
Zdravljenje z zdravilom IRESSA mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil proti raku.
Treatment with Isentress should be started by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Isentress lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Treatment with Jetrea in the other eye is not recommended concurrently or within 7 days of the initial injection in order to monitor the post-injection course including the potential for decreased vision in the injected eye.
Sočasno zdravljenje drugega očesa z zdravilom JETREA ali zdravljenje drugega očesa v 7 dneh po začetni injekciji ni priporočljivo, zato da lahko spremljamo potek po injiciranju, vključno z možnim poslabšanjem vida injiciranega očesa.
Treatment with Kaletra should be prescribed by a doctor who has experience in the management of HIV infection.
Uporabo zdravila Kaletra mora predpisati zdravnik, ki ima izkušnje z zdravljenjem okužb z virusom HIV.
Treatment with Ketoconazole HRA can be stopped abruptly without a need for progressive dose decrease where a change in the therapeutic strategy (eg surgery) is desired.
Zdravljenje z zdravilom Ketokonazol HRA se lahko prekine takoj, brez postopnega zmanjševanja odmerka, kadar je želena sprememba oblike zdravljenja (npr. kirurški poseg).
Treatment with ketoconazole in paediatric patients allowed normalisation of urinary free cortisol levels and clinical improvement, including recovering of growth rate and gonadal function, normalisation of blood pressure, Cushing’s syndrome features and weight loss in most of the cases.
Zdravljenje pediatričnih bolnikov s ketokonazolom je pri večini omogočilo normalizacijo ravni prostega kortizola v urinu in klinično izboljšanje, vključno z izboljšanjem hitrosti rasti in delovanja spolnih žlez, normalizacijo krvnega tlaka, izboljšanjem značilnosti Cushingovega sindroma in izgubo telesne mase.
Treatment with Keytruda must be started and supervised by a doctor experienced in the treatment of cancer.
Zdravljenje z zdravilom Keytruda mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Treatment with Kiovig should be started and monitored by a doctor experienced in treating immunodeficiency disorders.
Zdravljenje z zdravilom Kiovig mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem bolezni imunske pomanjkljivosti.
Treatment with Kuvan may decrease blood phenylalanine levels below the desired therapeutic level.
Zdravljenje z zdravilom Kuvan lahko zniža raven fenilalanina v krvi pod želeno terapevtsko raven.
Treatment with Kuvan must be started and supervised by a doctor who has experience in treating PKU and BH4 deficiency.
Zdravljenje z zdravilom Kuvan mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem fenilketonurije in pomanjkanja BH4.
Treatment with Kyprolis combined with lenalidomide and dexamethasone for longer than 18 cycles should be based on an individual benefit-risk assessment, as the data on the tolerability and toxicity of carfilzomib beyond 18 cycles are limited (see section 5.1).
Za več kot 18 ciklusov trajajoče zdravljenje z zdravilom Kyprolis v kombinaciji z lenalidomidom in deksametazonom se je treba odločiti na podlagi individualne ocene koristi in tveganj, ker so podatki o prenosljivosti in toksičnosti karfilzomiba po več kot 18 ciklusih omejeni (glejte poglavje 5.1).
Treatment with Lamivudine Teva can reduce the amount of hepatitis B virus in your body.
Zdravljenje z zdravilom Lamivudin Teva lahko zmanjša količino virusa hepatitisa B v telesu.
Treatment with Lamivudine Teva Pharma B.V. should be initiated by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Lamivudine Teva Pharma B.V. lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Treatment with liraglutide alone and in combination with one or two oral antidiabetic drugs resulted in a reduction in fasting plasma glucose of 13­43.5 mg/dl (0.72­2.42 mmol/l).
Zdravljenje z liraglutidom samim in skupaj z enim ali dvema peroralnima antidiabetikoma je zmanjšalo koncentracijo glukoze v plazmi na tešče za 13-43,5 mg/dl (0,72-2,42 mmol/l).
Treatment with Lojuxta should be initiated and monitored by a physician experienced in the treatment of lipid disorders;
Zdravljenje z zdravilom Lojuxta mora uvesti in spremljati zdravnik z izkušnjami z zdravljenjem lipidnih motenj;
Treatment with Lonsurf plus BSC resulted in a statistically significant prolongation of PS <2 in comparison to placebo plus BSC.
Zdravljenje z zdravilom Lonsurf in BSC je povzročilo statistično značilno podaljšanje PS < 2 v primerjavi s placebom in z BSC.
Treatment with Lonsurf should continue for as long as benefits can be seen and the side effects are tolerable.
Zdravljenje z zdravilom Lonsurf naj se nadaljuje, dokler so vidne koristi in dokler je neželene učinke mogoče prenašati.
Treatment with Lucentis should be stopped if the patient is not benefitting from it.
Zdravljenje z zdravilom Lucentis je treba prekiniti, če bolnik od njega nima nobenih koristi.
Treatment with lumacaftor/ivacaftor resulted in no significant improvement in ppFEV1 relative to placebo in patients with CF heterozygous for the F508del mutation in the CFTR gene (treatment difference 0.60 [P=0.5978]) and no meaningful improvements in BMI or weight (see section 4.4).
Zdravljenje z lumakaftorjem/ivakaftorjem ni povzročilo niti signifikantnega izboljšanja ppFEV1 glede na placebo pri bolnikih s CF, heterozigotnih za mutacijo F508del na genu CFTR (razlika zaradi zdravljenja 0,60 [P=0,5978]) niti pomembnih izboljšanj ITM ali telesne mase (glejte poglavje 4.4).
Treatment with Lynparza is started no later than 8 weeks after finishing the last dose of the platinum- based chemotherapy.
Zdravljenje z zdravilom Lynparza se prične najkasneje 8 tednov po zadnjem odmerku kemoterapije na osnovi platine.
Treatment with MabThera in combination with methotrexate over multiple courses resulted in sustained improvements in the clinical signs and symptoms of RA, as indicated by ACR, DAS28-ESR and EULAR responses which was evident in all patient populations studied (Figure 2).
Zdravljenje z zdravilom MabThera v kombinaciji z metotreksatom v več ciklih je prineslo stalno izboljšanje kliničnih znakov in simptomov RA, kot so pokazali odzivi po ACR, DAS28-ESR in EULAR; to je bilo opazno v vseh raziskovanih populacijah bolnikov (slika 2).
Treatment with macitentan 10 mg at Month 6 resulted in a placebo-corrected mean increase in 6MWD of 22 meters (97.5% CI: 3 to 41; p = 0.0078).
Zdravljenje z macitentanom 10 mg je v 6. mesecu povzročilo za placebo popravljeno povprečno zvišanje 6MWD za 22 metrov (97,5 % IZ: 3 do 41; p = 0,0078).
Treatment with Mozobil should only be started and supervised by a doctor who has experience in treating cancer or blood disorders.
Zdravljenje z zdravilom Mozobil mora uvesti in nadzorovati zdravnik z izkušnjami z zdravljenjem raka ali krvnih motenj.
Treatment with MULTAQ can be initiated in an outpatient setting.
Zdravljenje z zdravilom MULTAQ je mogoče uvesti ambulantno.
Treatment with Multaq should be started and monitored under specialist supervision.
Zdravljenje z zdravilom Multaq mora uvesti in spremljati zdravnik specialist.
Treatment with Mycamine should be initiated by a physician experienced in the management of fungal infections.
Zdravljenje z zdravilom Mycamine mora uvesti zdravnik, ki ima izkušnje z obvladovanjem glivičnih okužb.
Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight (see Section 5.1).
Zdravljenje z zdravilom Mysimba je treba po 16 tednih prekiniti, če bolnik ni izgubil vsaj 5 % izhodiščne telesne mase (glejte poglavje 5.1).
Treatment with NeoRecormon is divided into two stages.
Zdravljenje z zdravilom NeoRecormon poteka v dveh stopnjah:
Treatment with Nespo is divided into two stages – correction and maintenance phase.
Zdravljenje z Nespom delimo na dve obdobji – obdobje korekcije in obdobje vzdrževanja.
Treatment with Nespo should be temporarily discontinued if haemoglobin levels exceed 13 g/dl (8.1 mmol/l).
Če koncentracija hemoglobina preseže 130 g/l (8,1 mmol/l), morate uporabo Nespa začasno prekiniti.
Treatment with Neulasta alone does not preclude thrombocytopenia and anaemia because full dose myelosuppressive chemotherapy is maintained on the prescribed schedule.
Zdravljenje s samim zdravilom Neulasta ne prepreči trombocitopenije in anemije, ker se hkrati vzdržuje mielosupresivna kemoterapija s polnimi odmerki po predpisani shemi.
Treatment with Nimvastid should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Nimvastid mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem alzheimerjeve bolezni ali demence pri bolnikih s parkinsonovo boleznijo.
Treatment with nitisinone was also found to result in reduced risk for the development of hepatocellular carcinoma (2.3 to 3.7-fold) compared to historical data on treatment with dietary restriction alone.
Poleg tega so odkrili, da zdravljenje z nitizinonom, v primerjavi s podatki o zdravljenju zgolj s predpisano dieto, zmanjšuje tveganje za razvoj hepatocelularnega karcinoma (2,3- do 3,7-krat).
Treatment with NovoEight will be started by a doctor who is experienced in the care of patients with haemophilia A. Always use this medicine exactly as your doctor has told you.
Zdravljenje z zdravilom NovoEight vam bo uvedel zdravnik, ki je izkušen v zdravljenju bolnikov s hemofilijo A. Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika.
Treatment with NovoSeven should be started under the supervision of a doctor who has experience in the treatment of haemophilia or bleeding disorders.
Zdravljenje z zdravilom NovoSeven se mora uvesti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hemofilije ali motenj strjevanja krvi.
Treatment with Nplate should be stopped after four weeks of treatment with the maximum dose of Nplate if the platelet count does not reach levels that are high enough to reduce the risk of bleeding.
Zdravljenje z zdravilom Nplate je treba po štirih tednih zdravljenja z največjim odmerkom prekiniti, če število trombocitov ne doseže ravni, ki je dovolj visoka za zmanjšanje tveganja krvavitev.
Treatment with Nplate should be supervised by a doctor who has experience in treating blood diseases.
Zdravljenje z zdravilom Nplate mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem krvnih bolezni.
Treatment with NRTIs should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Zdravljenje z NRTI-ji je treba v primeru simptomatske hiperlaktatemije in metabolične acidoze/laktacidoze, napredujoče hepatomegalije ali hitrega zviševanja vrednosti aminotransferaz prekiniti.
Treatment with nucleoside analogues should be discontinued when rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology occur.
Zdravljenje z nukleozidnimi analogi je treba prekiniti, če pride do hitrega porasta koncentracij aminotransferaz, napredujoče hepatomegalije ali metabolične acidoze/laktacidoze iz neznanega vzroka.
Treatment with nucleoside analogues should be discontinued when rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology occur.
Če se aminotransferaze hitro zvišujejo ali se pojavi progresivna hepatomegalija ali metabolična acidoza/laktacidoza neznane etiologije, je treba zdravljenje z nukleozidnimi analogi prekiniti.
Treatment with Nuedexta was effective in reducing patients’ PBA episodes which were reduced by nearly 50% more than in patients treated with placebo.
Zdravljenje z zdravilom Nuedexta je bilo učinkovito pri zmanjšanju števila epizod PBP, ki so se zmanjšale za skoraj 50 % bolj kot pri bolnikih, zdravljenih s placebom.
Treatment with Nuwiq was rated as ‘excellent’ or ‘good’ for 94% of bleeding episodes.
Zdravljenje z zdravilom Nuwiq so ocenili kot „odlično“ ali „dobro“ pri 94 % krvavitev.
Treatment with omeprazole 20 mg qd had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir).
Zdravljenje z 20 mg omeprazola enkrat na dan ni vplivalo na izpostavljenost darunavirju (sočasno z ritonavirjem) in amprenavirju (sočasno z ritonavirjem).
Treatment with omeprazole 40 mg qd had no effect on the exposure of lopinavir (with concomitant ritonavir).
Zdravljenje s 40 mg omeprazola enkrat na dan ni vplivalo na izpostavljenost lopinavirju (sočasno z ritonavirjem).
Treatment with Opdivo must be started and supervised by a doctor experienced in the use of cancer medicines.
Zdravljenje z zdravilom Opdivo mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Treatment with Orencia should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of rheumatoid arthritis or juvenile idiopathic arthritis.
Zdravljenje z zdravilom Orencia lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa ali juvenilnega idiopatskega artritisa.
Treatment with Orfadin leads to high levels of tyrosine in the blood (due to the medicine’s mode of action); this side effect is seen in more than 1 patient in 10.
Zdravljenje z zdravilom Orfadin lahko povzroči visoke koncentracije tirozina v krvi (zaradi načina delovanja zdravila); ta neželeni učinek je opažen pri 1 bolniku od 10.
Treatment with Orkambi also led to a reduction in the number of exacerbations (flares-up) requiring hospital admission or antibiotic therapy.
Zdravljenje z zdravilom Orkambi je tudi zmanjšalo število poslabšanj (izbruhov), zaradi katerih sta bila potrebna sprejem v bolnišnico ali zdravljenje z antibiotiki.
Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E and K).
Zdravljenje z orlistatom lahko potencialno vpliva na absorpcijo vitaminov, topnih v maščobah (A, D, E in K).
Treatment with Panacur Aquasol in chickens reduced worm counts by 91% for Ascaridia galli and 98% for Heterakis gallinarum.
Zdravljenje z zdravilom Panacur AquaSol je pri piščancih zmanjšalo število črvov za 91 % pri okužbi z Ascaridia galli ter za 98 % pri okužbi z Heterakis gallinarum.
Treatment with Pedea should only be carried out in a neonatal intensive care unit under the supervision of an experienced neonatologist.
Zdravljenje z zdravilom Pedea se lahko izvaja le v neonatalnih intenzivnih enotah pod nadzorom izkušenega neonatologa.
Treatment with Pemetrexed Accord should be discontinued if a patient experiences any haematologic or non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if
Zdravljenje z zdravilom Pemetreksed Accord moramo prekiniti, če bolnik izkusi kakršnokoli hematološko ali nehematološko toksičnost stopnje 3 ali 4 po 2 znižanjih odmerka ali nemudoma, če opazimo nevrološko toksičnost stopnje 3 ali 4.
Treatment with Pemetrexed Fresenius Kabi should be discontinued if a patient experiences any haematologic or non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.
Zdravljenje z zdravilom Pemetreksed Fresenius Kabi se prekinite, če bolnik izkusi kakršno koli hematološko ali nehematološko toksičnost stopnje 3 ali 4 po 2 znižanjih odmerka ali nemudoma, če se opazi nevrološko toksičnost stopnje 3 ali 4.
Treatment with Pemetrexed Sandoz should be discontinued if a patient experiences any haematologic or non- haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.
Zdravljenje z zdravilom Pemetreksed Sandoz moramo prekiniti, če bolnik izkusi kakršnokoli hematološko ali nehematološko toksičnost stopnje 3 ali 4 po 2 znižanjih odmerka ali nemudoma, če opazimo nevrološko toksičnost stopnje 3 ali 4.
Treatment with pemetrexed should be discontinued if a patient experiences any haematologic or non- haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.
Zdravljenje s pemetreksedom moramo prekiniti, če bolnik izkusi kakršnokoli hematološko ali nehematološko toksičnost stopnje 3 ali 4 po 2 znižanjih odmerka ali nemudoma, če opazimo nevrološko toksičnost stopnje 3 ali 4.
Treatment with Pergoveris should be initiated under the supervision of a doctor who has experience in the treatment of fertility problems.
Zdravljenje z zdravilom Pergoveris je treba uvesti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem težav s plodnostjo.
Treatment with Perjeta and trastuzumab resulted in a response rate of 24.2%, with a further 25.8% of patients experiencing stabilisation of disease lasting at least 6 months, indicating that Perjeta is active following progression on trastuzumab.
Zdravljenje z zdravilom Perjeta in trastuzumabom je dalo 24,2-% delež odgovora, pri nadaljnih 25,8 % bolnikov je prišlo do stabilizacije bolezni, ki je trajala vsaj 6 mesecev.
Treatment with Pexion should be started at a dose of 10 mg per kg bodyweight twice a day.
Na začetku zdravljenja z zdravilom Pexion je treba uporabiti odmerek 10 mg na kg telesne mase dvakrat na dan.
Treatment with PhotoBarr is a two-step process: the medicine is given first before it is activated using a laser.
Zdravljenje z zdravilom PhotoBarr poteka v dveh korakih: zdravilo se najprej injicira, nato pa se aktivira z laserjem.
Treatment with Pioglitazone Accord should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Zdravljenje z zdravilom Pioglitazon Accord je treba ponovno oceniti po treh do šest mesecih in ga pri bolnikih, ki od njega nimajo zadostne koristi, ukiniti.
Treatment with Pioglitazone Actavis should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Zdravljenje z zdravilom Pioglitazone Actavis Group je treba ponovno oceniti po treh do šest mesecih in ga pri bolnikih, ki od njega nimajo zadostne koristi, prekiniti.
Treatment with Plegridy can help to prevent you from getting worse, although it will not cure MS.
Zdravljenje z zdravilom Plegridy lahko pomaga preprečiti poslabšanje MS, vendar bolezni ne bo ozdravilo.
Treatment with Plegridy must not be started during pregnancy.
Zdravljenje z zdravilom Plegridy se ne sme uvesti med nosečnostjo.
Treatment with Pradaxa in patients with severe renal impairment (CrCL < 30 mL/min) is contraindicated (see section 4.3).
Zdravljenje bolnikov s hudo ledvično okvaro ( CrCl < 30 ml/min) je kontraindicirano (glejte poglavje 4.3).
Treatment with Pradaxa in patients with severe renal impairment (CrCL < 30 mL/min) is contraindicated (see section 4.3).
Zdravljenje bolnikov s hudo ledvično okvaro (CrCl < 30 ml/min) je kontraindicirano (glejte poglavje 4.3).
Treatment with prasugrel is generally not recommended for patients of ≥ 75 years of age.
Zdravljenje s prasugrelom na splošno ni priporočeno za bolnike stare ≥ 75 let.
Treatment with prednisolone may not sufficiently restore respiratory function in all cases, and in each individual case the use of medication with more rapid onset of action may need to be considered.
Lahko se zgodi, da zdravljenje s prednizolonom v nekaterih primerih ne bo dovolj izboljšalo delovanja dihal, zato je treba v posameznih primerih razmisliti o uporabi zdravila, ki začne delovati hitreje.
Treatment with Privigen as a replacement therapy should be started and monitored by a doctor experienced in treating immunodeficiency syndrome.
Zdravljenje z zdravilom Privigen kot nadomestnim zdravljenjem mora uvesti in nadzirati zdravnik, ki ima izkušnje z zdravljenjem sindroma imunske pomanjkljivosti.
Treatment with Procox is included as one of several measures necessary in such a strategy.
Zdravljenje s Procoxom je vključeno kot eden številnih ukrepov pri taki strategiji.
Treatment with PROCYSBI should continue life-long, as instructed by your doctor.
Zdravljenje z zdravilom PROCYSBI mora trajati vse življenje po navodilih zdravnika.
Treatment with Prometax should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Prometax mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
Treatment with propranolol resulted in a rapid improvement (within 7-14 days) in all patients and resolution of the target haemangioma was observed in 36.4% of patients by 3 months.
Zdravljenje s propranololom je povzročilo hitro izboljšanje (v 7 do 14 dneh) pri vseh bolnikih, izginotje ciljnega hemangioma pa je bilo opaženo pri 36,4 % bolnikov v 3 mesecih.
Treatment with Protopic may be associated with an increased risk of folliculitis and herpes viral infections (herpes simplex dermatitis [eczema herpeticum], herpes simplex [cold sores], Kaposi’s varicelliform eruption) (see section 4.8).
Zdravljenje z zdravilom Protopic lahko spremlja večje tveganje za folikulitis in herpes virusne okužbe (herpes simplex dermatitis [eczema herpeticum], herpes simplex [ocvirki], Kaposijev variceliformni izpuščaj) (glejte poglavje 4.8).
Treatment with Protopy may be associated with an increased risk of herpes viral infections (herpes simplex dermatitis [eczema herpeticum], herpes simplex [cold sores], Kaposi’s varicelliform eruption).
Zdravljenje s Protopyom lahko spremlja večje tveganje za herpesvirusne okužbe (herpes simplex dermatitis [eczema herpeticum], herpes simplex [ocvirki], Kaposijev variceliformni izpuščaj).
Treatment with Puregon and hCG should be continued for at least 3 to months before any improvement in spermatogenesis can be expected.
Zdravljenje z zdravilom Puregon in hCG mora trajati najmanj 3 do 4 mesece, preden lahko pričakujete izboljšanje spermatogeneze.
Treatment with Refludan should be started by a doctor who has experience in the treatment of coagulation (clotting) disorders.
Zdravljenje z zdravilom Refludan mora uvesti zdravnik. ki ima izkušnje z zdravljenjem koagulacijskih motenj (motenj strjevanja krvi).
Treatment with REGRANEX should be initiated and monitored by physicians (specialists or non- specialists) who are experienced in the management of diabetic wounds.
Zdravljenje z zdravilom REGRANEX mora uvesti in spremljati zdravnik (specialist ali nespecialist), ki ima izkušnje z zdravljenjem diabetičnih kožnih ulkusov.
Treatment with Replagal resulted in an 11.5 g decrease in left ventricular mass as measured by magnetic resonance imaging (MRI) in the controlled study, while patients receiving placebo exhibited an increase in left ventricular mass of 21.8 g.
V kontrolirani študiji je zdravljenje z zdravilom Replagal povzročilo zmanjšanje mase levega prekata za 11,5 g (izmerjeno z magnetnoresonančnim slikanjem (MRI), pri bolnikih, ki so prejemali placebo, pa je prišlo do povečanja mase levega prekata za 21,8 g.
Treatment with Revasc should be initiated under the guidance of a physician with experience in coagulation disorders.
Zdravljenje z Revascom je treba začeti pod nadzorstvom zdravnika, izkušenega v zdravljenju koagulacijskih motenj.